Literature DB >> 20739501

Improved diagnosis of Strongyloides stercoralis using recombinant antigen-based serologies in a community-wide study in northern Argentina.

Alejandro J Krolewiecki1, Roshan Ramanathan, Valeria Fink, Isabel McAuliffe, Silvana P Cajal, Kimberly Won, Marisa Juarez, Adriana Di Paolo, Laura Tapia, Norma Acosta, Rogan Lee, Patrick Lammie, David Abraham, Thomas B Nutman.   

Abstract

The serodiagnosis of Strongyloides stercoralis infection by enzyme-linked immunosorbent assays based on crude antigen (CrAg-ELISA), while useful, has been limited by the reliance on crude parasite extracts. Newer techniques such as the luciferase immunoprecipitation system assay (LIPS), based on a 31-kDa recombinant antigen (termed NIE) from S. stercoralis and/or the recombinant antigen S. stercoralis immunoreactive antigen (SsIR), or the NIE-ELISA have shown promise in controlled settings. We compared each of these serologic assays in individuals from both regions of the world in which S. stercoralis is endemic and those in which it is not. A comprehensive stool evaluation (sedimentation concentration, Baermann concentration with charcoal cultures, agar plate, and Harada-Mori) and four different serologic techniques using CrAg-ELISA or recombinant NIE-ELISA as well as LIPS using NIE alone or in combination with a second recombinant antigen (NIE/SsIR-LIPS) were compared among individuals with parasitologically proven infection (n = 251) and healthy controls from regions of the world in which the infection is nonendemic (n = 11). Accuracy was calculated for each assay. The prevalence of S. stercoralis infection was 29.4% among Argentinean stool samples (n = 228). Sedimentation concentration and Baermann were the most sensitive stool-based methods. NIE-LIPS showed the highest sensitivity (97.8%) and specificity (100%) of the serologic assays. The calculated negative predictive value was highest for both the NIE-LIPS and CrAg-ELISA (>97%) irrespective of disease prevalence. No cross-reactivity with soil-transmitted helminths was noted. NIE-LIPS compares favorably against the current CrAg-ELISA and stool evaluation, providing additional accuracy and ease of performance in the serodiagnosis of S. stercoralis infections irrespective of disease prevalence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739501      PMCID: PMC2952987          DOI: 10.1128/CVI.00259-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Characterization of a recombinant immunodiagnostic antigen (NIE) from Strongyloides stercoralis L3-stage larvae.

Authors:  Varatharajalu Ravi; Srinivasan Ramachandran; Robert W Thompson; John F Andersen; Franklin A Neva
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

2.  Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war.

Authors:  L L Pelletier; C B Baker; A A Gam; T B Nutman; F A Neva
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

3.  Screening for intestinal helminth infestation in a semi-urban cohort of HIV-infected people in Uganda: a combination of techniques may enhance diagnostic yield in the absence of multiple stool samples.

Authors:  Michael Brown; Joseph Bukusuba; Peter Hughes; Jessica Nakiyingi; Christine Watera; Alison Elliott; James Whitworth
Journal:  Trop Doct       Date:  2003-04       Impact factor: 0.731

Review 4.  Strongyloidiasis: a review of the evidence for Australian practitioners.

Authors:  Fay H Johnston; Peter S Morris; Richard Speare; James McCarthy; Bart Currie; Dan Ewald; Wendy Page; Karen Dempsey
Journal:  Aust J Rural Health       Date:  2005-08       Impact factor: 1.662

5.  Efficacy of stool examination for detection of Strongyloides infection.

Authors:  Y Sato; J Kobayashi; H Toma; Y Shiroma
Journal:  Am J Trop Med Hyg       Date:  1995-09       Impact factor: 2.345

Review 6.  Strongyloides stercoralis in the Immunocompromised Population.

Authors:  Paul B Keiser; Thomas B Nutman
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

7.  Evaluation of techniques for the diagnosis of Strongyloides stercoralis in human immunodeficiency virus (HIV) positive and HIV negative individuals in the city of Itajaí, Brazil.

Authors:  Jucelene Marchi Blatt; Geny Aparecida Cantos
Journal:  Braz J Infect Dis       Date:  2003-12       Impact factor: 1.949

8.  Clinical status and parasitic infection in a Wichí Aboriginal community in Salta, Argentina.

Authors:  N J Taranto; S P Cajal; M C De Marzi; M M Fernández; F M Frank; A M Brú; M C Minvielle; J A Basualdo; E L Malchiodi
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 Sep-Oct       Impact factor: 2.184

Review 9.  Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease.

Authors:  R M Genta
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

10.  Occurrence of Strongyloides stercoralis in Yunnan Province, China, and comparison of diagnostic methods.

Authors:  Peter Steinmann; Xiao-Nong Zhou; Zun-Wei Du; Jin-Yong Jiang; Li-Bo Wang; Xue-Zhong Wang; Lan-Hua Li; Hanspeter Marti; Jürg Utzinger
Journal:  PLoS Negl Trop Dis       Date:  2007-10-31
View more
  65 in total

1.  Comparative evaluation of Strongyloides ratti and S. stercoralis larval antigen for diagnosis of strongyloidiasis in an endemic area of opisthorchiasis.

Authors:  Chatanun Eamudomkarn; Paiboon Sithithaworn; Jiraporn Sithithaworn; Sasithorn Kaewkes; Banchob Sripa; Makoto Itoh
Journal:  Parasitol Res       Date:  2015-04-17       Impact factor: 2.289

2.  Serologic Monitoring of Public Health Interventions against Strongyloides stercoralis.

Authors:  Paola Vargas; Alejandro J Krolewiecki; Adriana Echazú; Marisa Juarez; Pamela Cajal; Jose F Gil; Nicolás Caro; Julio Nasser; Patrick Lammie; Rubén O Cimino
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

3.  Prevalence of Strongyloides stercoralis and other intestinal parasitic infections among mentally retarded residents in central institution of southern Iran.

Authors:  Azar Shokri; Khojasteh Sharifi Sarasiabi; Saeed Hosseini Teshnizi; Hamid Mahmoodi
Journal:  Asian Pac J Trop Biomed       Date:  2012-02

Review 4.  Strongyloidiasis: A Neglected Tropical Disease.

Authors:  Alejandro Krolewiecki; Thomas B Nutman
Journal:  Infect Dis Clin North Am       Date:  2019-03       Impact factor: 5.982

5.  Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia.

Authors:  Fernando Salvador; Elena Sulleiro; Adrián Sánchez-Montalvá; José María Saugar; Esperanza Rodríguez; Albert Pahissa; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

Review 6.  Innate and adaptive immunity to the nematode Strongyloides stercoralis in a mouse model.

Authors:  Sandra Bonne-Année; Jessica A Hess; David Abraham
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

7.  Side Benefits of Mass Drug Administration for Lymphatic Filariasis on Strongyloides stercoralis Prevalence on Pemba Island, Tanzania.

Authors:  Beatrice Barda; Marco Albonico; Dora Buonfrate; Shaali M Ame; Said Ali; Benjamin Speich; Jennifer Keiser
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

8.  Diagnosis of Strongyloides stercoralis: Detection of parasite-derived DNA in urine.

Authors:  Nilanjan Lodh; Reynaldo Caro; Shterna Sofer; Alan Scott; Alejandro Krolewiecki; Clive Shiff
Journal:  Acta Trop       Date:  2016-07-22       Impact factor: 3.112

Review 9.  Human infection with Strongyloides stercoralis and other related Strongyloides species.

Authors:  Thomas B Nutman
Journal:  Parasitology       Date:  2016-05-16       Impact factor: 3.234

10.  Use of dried blood spots to define antibody response to the Strongyloides stercoralis recombinant antigen NIE.

Authors:  Kate Mounsey; Therese Kearns; Melanie Rampton; Stacey Llewellyn; Mallory King; Deborah Holt; Bart J Currie; Ross Andrews; Thomas Nutman; James McCarthy
Journal:  Acta Trop       Date:  2014-07-19       Impact factor: 3.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.